Rallybio (RLYB) has released an update to notify the public and investors about termination and asset disposition expenses.
Rallybio is streamlining its operations by focusing on its Phase 2-ready clinical programs and reducing its workforce by about 45%, which is expected to cost approximately $3.3 million in severance-related charges, to be largely recognized in the first quarter of 2024. These changes reflect a strategic pivot and are based on management’s expectations, but are subject to the usual business uncertainties and risks as detailed in the company’s SEC filings.
For further insights into RLYB financials, check out TipRanks’ Financials page.
For a comprehensive understanding of the announcement, you can read the full document here.
